Claims for Patent: 7,414,107
✉ Email this page to a colleague
Summary for Patent: 7,414,107
Title: | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
Abstract: | The invention is directed to a pharmacologically active peptide conjugate having a reduced tendency towards enzymatic cleavage comprising a pharmacologically active peptide sequence (X) and a stabilizing peptide sequence (Z) of 4-20 amino acid residues covalently bound to X. |
Inventor(s): | Larsen; Bjarne Due (Vanlose, DK) |
Assignee: | Zealand Pharma A/S (DK) |
Application Number: | 11/007,772 |
Patent Claims: | 1. A method for the preparation of a pharmacologically active peptide conjugate (X-Z) comprising the steps of: a) coupling an additional N-.alpha.-protected amino acid in
the carboxyl activated form or an N-.alpha.-protected dipeptide in the C-terminal activated form to an immobilised peptide sequence H-Z-SSM, thereby forming an immobilized N-.alpha.-protected peptide fragment, b) removing the N-.alpha.-protecting group,
thereby forming an immobilised peptide fragment having an unprotected N-terminal end, c) coupling an additional N-.alpha.-protected amino acid in the carboxyl activated form or an additional N-.alpha.-protected dipeptide in the C-terminal activated form
to the N-terminal end of the immobilised peptide fragment, and repeating the removal/coupling step procedure in steps b) and c) until the desired peptide sequence X is obtained, and d) cleaving off the peptide conjugate from the solid support material,
wherein X is a pharmacologically active peptide sequence consisting of 3 to 50 amino acid units, Z is a stabilising peptide covalently bound by its N terminus to the C terminus end of X and consisting of 4 to 15 amino acid residues, wherein Z consists
of(1) residues selected from Glu, Lys, and Met, or (2) Z is a sequence selected from: (i) Lys.sub.4-10, (ii) (Lys-Xaa).sub.m, (iii) (Xaa-Lys).sub.m, (iv) Lys.sub.p-Xaa.sub.q, (v) Xaa.sub.p-Lys.sub.q, (vi) Xaa.sup.1-Lys-Xaa.sup.2-Lys, (vii)
Xaa.sup.1-Lys-Xaa.sup.2-Lys-Xaa.sup.2, (viii) Xaa.sup.1-Lys-Xaa.sup.2-Lys-Xaa.sup.2-Lys, (ix) Xaa.sup.1-Xaa.sup.2-Lys-Xaa.sup.2, (x) Xaa.sup.1-Xaa.sup.2-Lys-Xaa.sup.2-Lys, (xi) Xaa.sup.1-Xaa.sup.1-Lys-Xaa.sup.2-Lys-Xaa.sup.2, (xii)
Lys-Xaa.sup.2-Lys-Xaa.sup.1, (xiii) Lys-Xaa.sup.2-Lys-Xaa.sup.2-Xaa.sup.1, (xiv) Lys-Xaa.sup.2-Lys-Xaa.sup.2-Lys-Xaa.sup.1, (xv) Xaa.sup.2-Lys-Xaa.sup.2-Xaa.sup.1, (xvi) Xaa.sup.2-Lys-Xaa.sup.2-Lys-Xaa.sup.1, and (xvii)
Xaa.sup.2-Lys-Xaa.sup.1-Lys-Xaa.sup.2-Xaa.sup.1, wherein each of Xaa, Xaa.sup.1, and Xaa.sup.2 is, independently, selected from the group consisting of Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Arg, His, and Met; each of p and q is, independently, an integer
from 1 to 14, with the proviso that p+q is from 4 to 15; m is an integer in the range from 2 to 7; and wherein, X is selected from the group consisting of GLP-1-(7-36), AF 12505 (Ile-Glu-Gly-Pro-Thr-Leu-Arg-Gln-Trp-Leu-Ala-Ala-Arg-Ala) (SEQ ID NO: 14),
insulin-like growth factor I (57-70) (Ala-Leu-Leu-Glu-Thr-Tyr-Cys-Ala-Thr-Pro-Ala-Lys-Ser-Glu) (SEQ ID NO: 15), insulin-like growth factor I (30-41) (Gly-Tyr-Gly-Ser-Ser-Ser-Arg-Arg-Ala-Pro-Gln-Thr) (SEQ ID NO: 16), insulin-like growth factor I (24-41)
(Tyr-Phe-Asn-Lys-Pro-Thr-Gly-Tyr-Gly-Ser-Ser-Ser-Arg-Arg-Ala-Pro-Gln-Thr) (SEQ ID NO: 17), insulin-like growth factor II (33-40) (Ser-Arg-Val-Ser-Arg-Arg-Ser-Arg) (SEQ ID NO: 18), insulin-like growth factor II (33-40)
(Tyr-Ser-Arg-Val-Ser-Arg-Arg-Ser-Arg) (SEQ ID NO: 19), insulin-like growth factor II (69-84) (Asp-Val-Ser-Thr-Pro-Pro-Thr-Val-Leu-Pro-Asp-Asn-Phe-Pro-Arg-Tyr) (SEQ ID NO: 20), growth hormone (GH)-releasing peptide-6 (GHRP-6)
(His-DTrp-Ala-Trp-DPhe-Lys-NH2) (SEQ ID NO: 21), beta-Interleukin I (163-171) (Val-Gln-Gly-Glu-Glu-Ser-Asn-Asp-Lys) (SEQ ID NO: 22), beta-Interleukin II (44-56) (Ile-Leu-Asn-Gly-Ile-Asn-Asn-Tyr-Lys-Asn-Pro-Lys-Leu) (SEQ ID NO: 23), Interleukin II (60-70)
(Leu-Thr-Phe-Lys-Phe-Tyr-Met-Pro-Lys-Lys-Ala) (SEQ ID NO: 24), exendin-4 (GLP-1 analog) (His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-- Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pr- o-Pro-Ser-NH2)
(SEQ ID NO: 25), exendin-3 (GLP-I analog) (His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-- Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pr- o-Pro-Ser) (SEQ ID NO: 26), epidermal growth factor (20-31)
Cys(Acm)-Met-His-Ile-Glu-Ser-Leu-Asp-Ser-Tyr-Thr-Cys(Acm) (SEQ ID NO: 27), bivalirudin (Hirulog) (D-Phe-Pro-Arg-Pro-(Gly) 4-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu) (SEQ ID NO: 28), hirulog-1
D-Phe-Pro-Arg-Pro-(Gly)4-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Ty- r-Leu (SEQ ID NO: 29), C-type natriuretic peptide (1-53) (CNP) (Asp-Leu-Arg-Val-Asp-Thr-Lys-Ser-Arg-Ala-Ala-Trp-Ala-Arg-Leu-Gln-Glu-His--
Pro-Asn-Ala-Arg-Lys-Tyr-Lys-Gly-Ala-Asn-Lys-Lys-Gly-Leu-Ser-Lys-Gly-Cys-Ph- e-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys; Disulfide bridge: Cys37-Cys53) (SEQ ID NO: 30), "Mini ANP"
(Met-Cys-His-cyclohexylAla-Gly-Gly-Arg-Met-Asp-Arg-Ile-Ser-Cys-Tyr-Arg, disulfide bridge cys2-cys13) (SEQ ID NO: 31), thymosin alpha 1 (TA1) (Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Lys-Asp-Leu-Lys-Glu-L-
ys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn) (SEQ ID NO: 33), Cys-Phe-Ile-Gln-Asn-Cys-Pro-Orn-Gly-NH2, Disulfide bridge: Cysl-Cys6) (SEQ ID NO: 34), octreotide (201-995) (DPhe-Cys-Phe-DTrp-Lys-Thr-Cys-Thr-ol; disulfide bridge: Cys2-Cys7) (SEQ ID NO: 35),
calcitonin gene-related peptide (CGRP) Ala-Cys-Asp-Thr-Ala-Thr-Cys-Vla-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-S- er-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe- -NH2; Disulfide bridge: Cys2-Cys7) (SEQ ID NO: 36), nociceptin
(also known as Orphanin FQ, Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Leu-Ala-Asn-Gln) (SEQ ID NO: 39), angiotensinogen (1-13) (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Val-Ile-His) (SEQ ID NO: 40), adrenomodullin (1-12)
(Tyr-Arg-Gln-Ser-Met-Asn-Asn-Phe-Gln-Gly-Leu-Arg) (SEQ ID NO: 41), antiarrhythmic peptide (AAP) (Gly-Pro-Hyp-Gly-Ala-Gly) (SEQ ID NO: 42), Antagonist G (Arg-DTrp-(nMe) Phe-DTrp-Leu-Met-NH.sub.2), indolicidin
(Ile-Leu-Pro-Trp-Lys-Trp-Pro-Trp-Trp-Pro-Trp-Arg-Arg-NH2) (SEQ ID NO: 43), osteocalcin (37-49) (Gly-Phe-Gln-Glu-Ala-Tyr-Arg-Arg-Phe-Tyr-Gly-Pro-Val) (SEQ ID NO: 44), cortistatin 29 (1-13) (Glp)-Glu-Arg -Pro-Pro-Leu-Gln-Gln-Pro-Pro-His-Arg-Asp) (SEQ ID
NO: 45), cortistatin 14 Pro-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Ser-Ser-Cys-Lys; disulfide bridge: Cys2-Cys13 (SEQ ID NO: 46), PD-145065 (Ac-D-Bhg-Leu-Asp-Ile-Ile-Trp) (SEQ ID NO: 47), PD-142893 (Ac-D-Dip-Leu-Asp-Ile-Ile-Trp) (SEQ ID NO: 48), fibrinogen
binding inhibitor peptide (His-His-Leu-Gly-Gly-Ala-Lys-Gln-Ala-Gly-Asp-Val) (SEQ ID NO: 49), leptin (93-105) (Asn-Val-Ile-Gln-Lle-Ser-Asn-Asp-Leu-Glu-Asn-Leu-Arg) (SEQ ID NO: 50), GR 83074 (Boc-Arg-Ala-DTrp-Phe-DPro-Pro-Nle-NH2) (SEQ ID NO:51)
Tyr-W-MIF-1 (Tyr-Pro-Trp-Gly-NH2) (SEQ ID NO: 52), parathyroid hormone related peptide (107-111) (Thr-Arg-Ser-Ala-Trp) (SEQ ID NO: 53), angiotensinogen (1-14) Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Asn (SEQ ID NO: 54), enkephalin,
Leu-enkephalin, Met-enkephalin, angiotensin I, angiotensin II, vasopressin, endothelin, vasoactive intestinal peptide, neurotensin, insulin, gramicidin, paracelsin, delta-sleep inducing peptide, gonadotropin-releasing hormone, human parathyroid hormone
(1-34), EMP-1, Atrial natriuretic peptide, human brain natriuretic peptide, cecropin, kinetensin, neurophysins, elafin, guamerin, atriopeptin I, atriopeptin II, atriopeptin III, deltorphin I, deltorphin II, vasotocin, bradykinin, dynorphin, dynorphin A,
dynorphin B, growth hormone release factor, growth hormone, growth hormone releasing peptide, oxytocin, calcitonin, calcitonin gene-related peptide, calcitonin gene-related peptide II, growth hormone releasing peptide, tachykinin, cholecystokinin,
corticotropin releasing factor, diazepam binding inhibitor fragment, FMRF-amide, galanin, gastric releasing polypeptide, gastric inhibitory polypeptide, gastrin, gastrin releasing peptide, glucagon, glucagon-like peptide-1, glucagon-like peptide-2, LHRH,
melanin concentrating hormone, morphine modulating peptides, motilin, neurokinin A, neurokinin B, neuromedin B, neuromedin C, neuromedin K, neuromedin N, neuromedin U, neuropeptide K, neuropeptide Y, pituitary adenylate cyclase activating polypeptide,
pancreatic polypeptide, peptide YY, peptide histidine-methionine amide, secretin, somatostatin, substance K, thyrotropin-releasing hormone, kyotorphin, melanostatin, and truncated analogs thereof.
2. The method according to claim 1, wherein Z is Lys.sub.4 (SEQ ID NO: 55), Lys.sub.5 (SEQ ID NO: 56) or Lys.sub.6 (SEQ ID NO: 62). 3. The method according to claim 1, wherein Z is Lys.sub.6 (SEQ ID NO: 62). 4. The method according to claim 1, wherein said peptide conjugate is represented by one of the following formulae: (i) H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser- -Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-G- lu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-Lys.sub.6-NH2 (GHRH(1-44)(Human)-Lys.sub.6-NH2) (SEQ ID NO: 88); (ii) H-Tyr-Ala-Asp-Ala-Lle-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser- -Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-G- lu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-Glu.sub.6-NH2 (GHRH (1-44)(Human)-Glu.sub.6-NH2) (SEQ ID NO: 89); (iii) H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met- -Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-Lys.sub.6- -OH (PTH(1-34)(Human)-Lys.sub.6-OH) (SEQ ID NO: 91); (iv) H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala- -Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Lys.sub.6OH (GLP-1-(7-36)(Human)-Lys.sub.6-OH) (SEQ ID NO: 92); (v) H-Gly-Gly-Thr-Tyr-Ser-Cys-(Acm)-His-Phe-Gly-Pro-Leu-Thr-Trp-Val-Cys (Acm)-Lys-Pro-Gln-Gly-Gly-Lys.sub.6-OH (EMP-1-Lys.sub.6-OH) (SEQ ID NO: 93); (vi) H-Aib-His-2-D-Nal-D-Phe-Lys-(Lys).sub.6-NH2 (GHRP-(Lys).sub.6-NH2) (SEQ ID NO: 96); (vii) H-Tyr-Gly-Gly-Phe-Leu-Lys-Lys-Glu-Glu-Glu-LysOH (Leu-enkephalin-Lys-Lys-Glu-Glu-Glu-Lys-OH) (SEQ ID NO: 97); (viii) H-Tyr-Gly-Gly-Phe-Leu-Lys-Glu-Glu-Glu-Glu-Lys-OH (Leu-enkephalin-Lys-Glu-Glu-Glu-Glu-Lys-OH) (SEQ ID NO: 98); (ix) H-Tyr-Gly-Gly-Phe-Leu-Lys-Glu-Lys-Glu-Lys-Glu-OH (Leu-enkephalin-(Lys-Glu).sub.3 (SEQ ID NO:99); (x) Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-(Lys).sub.6-OH (GnRH-Lys.sub.6-OH) (SEQ ID NO: 103); (xi) Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-(Lys-Glu).sub.3 (GnRH-(Lys-Glu).sub.3-OH) (SEQ ID NO: 104); and (xii) H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met- -Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-(Lys-Glu)- .sub.3-OH (PTH 1-34 human-(Lys-Glu).sub.3-OH) (SEQ ID NO: 105). 5. The method according to claim 1, wherein Z is (Lys).sub.n in which n is an integer from 4 to 10. 6. The method according to claim 5, wherein n is an integer from 4 to 8. 7. The method according to claim 6, wherein n is an integer from 4 to 6. 8. The method according to claim 1, wherein X is glucagon or a truncated analog thereof and Z is (Lys).sub.n in which n is an integer from 4 to 10. |
Details for Patent 7,414,107
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Nps Pharmaceuticals, Inc. | NATPARA | parathyroid hormone | For Injection | 125511 | 01/23/2015 | ⤷ Try a Trial | 2018-03-09 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.